Summary
A Phase III, open label, randomized, controlled, multicenter study to assess the safety and efficacy of the Study Drug monotherapy versus the physician’s choice to treat platinum-sensitive relapsed ovarian cancer.
Register to download
Embracing a Risk-based Approach
You may also be interested in:
Fact Sheet
Vaccine Solutions
PRA’s Vaccine Solutions group understands the unique challenges and characteristics of vaccine development. Right from the start, our experts will…
View Resource
Case Study
PRA’s Unique Model Leads to Client Satisfaction
A randomized, multi-center, double-blind study to compare the efficacy and safety of Study Drug A and Study Drug B as monotherapy in newly diagnosed…
View Resource
Case Study
Overcoming Difficult Recruitment Challenges to Meet Vaccine Study Enrollment Goals
A randomized, observer-blind, placebo-controlled, multi-center, multi-national, Phase III trial evaluating the efficacy, immunogenicity, and safety…
View Resource
View all related content and resources for Study Design
Explore Insights